ThermoGenesis’s MarrowXpress (MXP) device is used to process bone marrow in a laboratory setting. The MXP is a derivative of the company’s approved AutoXpress platform that is used to reduce volume and collect stem cells from umbilical cord blood.
Earlier June 2008, ThermoGenesis has submitted a 510(k) pre-market notification application to the FDA seeking regulatory clearance in the US.
William Osgood, CEO of ThermoGenesis, said: “We have had very encouraging feedback from a number of European centers at which bone marrow clinical trials are either underway or planned. With this approval, we can now ramp up those discussions and initiate a formal launch for the MXP in Europe.”